What is the current status of dengue vaccine development?

What is the current status of dengue vaccine development?

One dengue vaccine has been licensed, Dengvaxia® (CYD-TDV), developed by Sanofi Pasteur. Approximately five additional dengue vaccine candidates are in clinical development, with two candidates (developed by NIH/Butantan and Takeda) now in Phase III trials.

What is the current strategy for dengue vaccine development and why?

Currently, the conventional vaccine strategies, such as the attenuated, chimeric, DNA, inactivated and viral vector vaccines have been developed for the prevention of infection from all four dengue serotypes in humans via stimulation of anti-E neutralizing antibodies directly against either the DENV virions or the …

Why there is no vaccine for dengue virus?

The dengue virus consists of four serotypes, DENV-1, DENV-2, DENV-3 and DENV-4. The available vaccine only provides immunity against one serotype, which does not generate lasting immunity against the other three, making it only less effective.

WHO manufactured Dengvaxia?

Sanofi Pasteur Inc. (SNY) is the manufacturer of the Dengvaxia vaccine.

Who made the Dengvaxia vaccine?

What are the challenges in developing a dengue vaccine?

Unlike other highly effective vaccines developed against other flaviviruses, the development of a dengue vaccine is highly challenging due to that fact that the virus has four antigenically different serotypes (DENV1–4).

What company made Dengvaxia?

Is Dengvaxia safe?

Severe side effects may include anaphylaxis. Use is not recommended in people with poor immune function. Safety of use during pregnancy is unclear. Dengvaxia is a weakened but live vaccine and works by triggering an immune response against four types of dengue virus.

Is dengue vaccine FDA approved?

The U.S. Food and Drug Administration (FDA) approved Dengvaxia for use in children and adolescents 9–16 years old with laboratory-confirmed evidence of a previous dengue virus infection and living in areas of the United States where dengue is common.

WHO made the Dengvaxia vaccine?

Who manufactured Dengvaxia?

Is Dengvaxia recommended?

Dengvaxia is recommended as a 3-dose vaccination series, administered 6 months apart at 0, 6, and 12 months, for the selected pediatric population.